These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29152767)

  • 1. Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.
    Younossi ZM; Afendy A; Stepanova M; Racila A; Nader F; Gomel R; Safer R; Lenderking WR; Skalicky A; Kleinman L; Myers RP; Subramanian GM; McHutchison JG; Levy C; Bowlus CL; Kowdley K; Muir AJ
    Hepatology; 2018 Jul; 68(1):155-165. PubMed ID: 29152767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC.
    Younossi ZM; Stepanova M; Younossi I; Racila A
    Hepatol Commun; 2023 Feb; 7(2):e0049. PubMed ID: 36724122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a Primary Biliary Cholangitis-Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC.
    Younossi ZM; Stepanova M; Younossi I; Racila A
    Clin Transl Gastroenterol; 2024 Sep; 15(9):e1. PubMed ID: 38738764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis.
    Cheung AC; Patel H; Meza-Cardona J; Cino M; Sockalingam S; Hirschfield GM
    Dig Dis Sci; 2016 Jun; 61(6):1692-9. PubMed ID: 26743764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review.
    Isa F; Turner GM; Kaur G; Kyte D; Slade A; Pankhurst T; Kerecuk L; Keeley T; Ferguson J; Calvert M
    Health Qual Life Outcomes; 2018 Jul; 16(1):133. PubMed ID: 29976215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.
    Kalaitzakis E; Benito de Valle M; Rahman M; Lindkvist B; Björnsson E; Chapman R; Kontodimopoulos N
    Qual Life Res; 2016 Apr; 25(4):947-57. PubMed ID: 26471264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Simple Cholestatic Complaints Score is a valid and quick patient-reported outcome measure in primary sclerosing cholangitis.
    van Munster KN; Dijkgraaf MGW; van Gennep S; Beuers U; Ponsioen CY
    Liver Int; 2020 Nov; 40(11):2758-2766. PubMed ID: 32841496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Modular Health-Related Quality of Life Instrument for Electronic Assessment and Treatment Monitoring: Web-Based Development and Psychometric Validation of Core Thrive Items.
    Wicks P; McCaffrey S; Goodwin K; Black R; Hoole M; Heywood J
    J Med Internet Res; 2019 Jan; 21(1):e12075. PubMed ID: 30681962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.
    Younossi ZM; Stepanova M; Henry L; Racila A; Lam B; Pham HT; Hunt S
    Liver Int; 2017 Aug; 37(8):1209-1218. PubMed ID: 28211165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis.
    Raszeja-Wyszomirska J; Wunsch E; Krawczyk M; Rigopoulou EI; Bogdanos D; Milkiewicz P
    Liver Int; 2015 Jun; 35(6):1764-71. PubMed ID: 25388280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
    Bayraktar Y; Arslan S; Saglam F; Uzunalimoglu B; Kayhan B
    Hepatogastroenterology; 1998; 45(24):2064-72. PubMed ID: 9951867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    Younossi ZM; Stepanova M; Younossi I; Racila A
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2093-2100.e3. PubMed ID: 30639779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Kim HP; Lieber SR; Rogers ME; Moon AM; Loiselle M; Walker J; Assis DN; Safer R; Gomel R; Evon DM
    Hepatol Commun; 2020 Oct; 4(10):1502-1515. PubMed ID: 33024919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.
    de Vries AB; Janse M; Blokzijl H; Weersma RK
    World J Gastroenterol; 2015 Feb; 21(6):1956-71. PubMed ID: 25684965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life among patients with primary sclerosing cholangitis.
    Haapamäki J; Tenca A; Sintonen H; Barner-Rasmussen N; Färkkilä MA
    Liver Int; 2015 Sep; 35(9):2194-201. PubMed ID: 25546575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV.
    Younossi ZM; Stepanova M; Younossi I; Racila A
    J Viral Hepat; 2021 Mar; 28(3):484-492. PubMed ID: 33306234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C.
    Younossi ZM; Stepanova M; Henry L
    Value Health; 2016; 19(5):544-51. PubMed ID: 27565271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q-SF).
    Gelhorn HL; Roberts LJ; Khandelwal N; Revicki DA; DeRogatis LR; Dobs A; Hepp Z; Miller MG
    J Sex Med; 2017 Aug; 14(8):1046-1058. PubMed ID: 28760247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients.
    Paziewska A; Habior A; Rogowska A; Zych W; Goryca K; Karczmarski J; Dabrowska M; Ambrozkiewicz F; Walewska-Zielecka B; Krawczyk M; Cichoz-Lach H; Milkiewicz P; Kowalik A; Mucha K; Raczynska J; Musialik J; Boryczka G; Wasilewicz M; Ciecko-Michalska I; Ferenc M; Janiak M; Kanikowska A; Stankiewicz R; Hartleb M; Mach T; Grzymislawski M; Raszeja-Wyszomirska J; Wunsch E; Bobinski T; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Jan; 10(1):2. PubMed ID: 28056976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease.
    Kim WR; Lindor KD; Malinchoc M; Petz JL; Jorgensen R; Dickson ER
    Hepatology; 2000 Nov; 32(5):924-9. PubMed ID: 11050040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.